RU2622015C2 - Способ лечения пролиферативного заболевания - Google Patents

Способ лечения пролиферативного заболевания Download PDF

Info

Publication number
RU2622015C2
RU2622015C2 RU2014117707A RU2014117707A RU2622015C2 RU 2622015 C2 RU2622015 C2 RU 2622015C2 RU 2014117707 A RU2014117707 A RU 2014117707A RU 2014117707 A RU2014117707 A RU 2014117707A RU 2622015 C2 RU2622015 C2 RU 2622015C2
Authority
RU
Russia
Prior art keywords
treatment
braf
braf inhibitor
mutation
weeks
Prior art date
Application number
RU2014117707A
Other languages
English (en)
Russian (ru)
Other versions
RU2014117707A (ru
Inventor
Даррин Стьюарт
Мегхна Дас ТХАКУР
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2014117707A publication Critical patent/RU2014117707A/ru
Application granted granted Critical
Publication of RU2622015C2 publication Critical patent/RU2622015C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2014117707A 2011-11-11 2012-11-09 Способ лечения пролиферативного заболевания RU2622015C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161558619P 2011-11-11 2011-11-11
US61/558,619 2011-11-11
PCT/US2012/064269 WO2013070996A1 (en) 2011-11-11 2012-11-09 Method of treating a proliferative disease

Publications (2)

Publication Number Publication Date
RU2014117707A RU2014117707A (ru) 2015-12-20
RU2622015C2 true RU2622015C2 (ru) 2017-06-08

Family

ID=47279036

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014117707A RU2622015C2 (ru) 2011-11-11 2012-11-09 Способ лечения пролиферативного заболевания

Country Status (10)

Country Link
US (1) US11007194B2 (enExample)
EP (1) EP2776037B1 (enExample)
JP (1) JP6150813B2 (enExample)
CN (2) CN103917236A (enExample)
AU (1) AU2012335663B2 (enExample)
BR (1) BR112014011223A8 (enExample)
CA (1) CA2855243C (enExample)
MX (1) MX354725B (enExample)
RU (1) RU2622015C2 (enExample)
WO (1) WO2013070996A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
IN2015DN00450A (enExample) * 2012-08-07 2015-06-26 Novartis Ag
BR112018074941A2 (pt) 2016-06-03 2019-03-12 Caponigro Giordano combinações farmacêuticas
US11590133B2 (en) * 2016-12-11 2023-02-28 Memorial Sloan Kettering Cancer Center Methods and compositions for treatment of BRAF mutant cancers
WO2020011141A1 (zh) * 2018-07-12 2020-01-16 深圳市塔吉瑞生物医药有限公司 一种二芳基吡唑化合物及包含该化合物的组合物及其用途
TWI817018B (zh) 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
CA3163703A1 (en) * 2020-01-07 2021-07-15 Steve Kelsey Shp2 inhibitor dosing and methods of treating cancer
MX2022015703A (es) 2020-06-09 2023-01-24 Array Biopharma Inc Compuestos para el tratamiento de enfermedades y trastornos asociados a braf.
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
WO2024186319A1 (en) 2023-03-09 2024-09-12 Minneamrita Therapeutics Llc Drug combination for treatment of gastric cancer
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib
AU2025207356A1 (en) 2024-01-11 2026-08-06 Minneamrita Therapeutics Llc Triptolide formulations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2402602C1 (ru) * 2009-02-12 2010-10-27 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Rac, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН
WO2011025927A1 (en) * 2009-08-28 2011-03-03 Irm Llc Compounds and compositions as protein kinase inhibitors

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
NZ501112A (en) 1997-05-22 2002-10-25 G Substituted pyrazoles as p38 kinase inhibitors
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US6316435B2 (en) 1999-02-24 2001-11-13 Supergen, Inc. Combination therapy for lymphoproliferative diseases
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
NZ552335A (en) 2001-10-25 2008-11-28 Novartis Ag Combinations comprising a selective COX-2 inhibitor and a microtubule interfering agent
JP4399265B2 (ja) 2001-12-21 2010-01-13 ヴァーナリス（ケンブリッジ）リミテッド ３，４−ジアリールピラゾール、および癌の治療におけるそれらの使用
EA200600495A1 (ru) 2003-09-23 2006-10-27 Новартис Аг Комбинация ингибитора vegf рецептора с химиотерапевтическим агентом
AU2004289539C1 (en) 2003-11-14 2012-06-07 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
CA2551948A1 (en) 2004-01-09 2005-07-28 Novartis Ag Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as igf-ir inhibitors
MXPA06014247A (es) 2004-06-10 2007-03-12 Irm Llc Compuestos y composiciones como inhibidores de la proteina quinasa.
WO2006102079A1 (en) 2005-03-17 2006-09-28 Novartis Ag N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase
US20070099856A1 (en) * 2005-05-13 2007-05-03 Gumerlock Paul H Combined treatment with docetaxel and an epidermal growth factor receptor kinase inhibitor using an intermittent dosing regimen
WO2007021966A1 (en) 2005-08-12 2007-02-22 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate hsp90 activity
RU2442574C2 (ru) 2005-08-22 2012-02-20 Новартис Аг ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ pН-ЗАВИСИМОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, МОДИФИКАТОР pН И ЗАМЕДЛЯЮЩИЙ АГЕНТ
EP1917258A2 (en) 2005-08-26 2008-05-07 SmithKline Beecham Corporation Pyrimidinyl-pyrazole inhibitors of aurora kinases
PE20070335A1 (es) 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
CA2643066A1 (en) 2006-03-16 2007-09-20 Pfizer Products Inc. Pyrazole compounds
CN101415411A (zh) 2006-04-05 2009-04-22 诺瓦提斯公司 用于治疗癌症的治疗剂组合
WO2007123892A2 (en) 2006-04-17 2007-11-01 Arqule Inc. Raf inhibitors and their uses
AU2007305016B2 (en) 2006-10-02 2011-11-03 Novartis Ag Compounds and compositions as protein kinase inhibitors
WO2008045627A2 (en) 2006-10-06 2008-04-17 Irm Llc Protein kinase inhibitors and methods for using thereof
CA2677651A1 (en) 2007-02-15 2008-08-21 Novartis Ag Combinations of therapeutic agents for treating cancer
US20090022789A1 (en) 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
BRPI0815042A2 (pt) 2007-08-01 2015-02-10 Pfizer Compostos de pirazol
BRPI0818340A2 (pt) 2007-10-19 2015-04-22 Abbott Gmbh & Co Kg Produto de dispersão sólida de fármacos baseados em n-aril uréia
CA2704436C (en) 2007-11-14 2016-01-05 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
WO2009115572A2 (en) 2008-03-21 2009-09-24 Novartis Ag Novel heterocyclic compounds and uses therof
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
EP2324008B1 (en) 2008-07-24 2012-05-09 Nerviano Medical Sciences S.R.L. 3,4-diarylpyrazoles as protein kinase inhibitors
KR20110038159A (ko) 2008-07-28 2011-04-13 길리애드 사이언시즈, 인코포레이티드 사이클로알킬리덴 및 헤테로사이클로알킬리덴 히스톤 데아세틸라아제 억제제 화합물
EP2350052B1 (en) 2008-09-29 2014-08-13 Boehringer Ingelheim International GmbH Antiproliferative compounds
EP2346495B2 (en) 2008-10-07 2023-05-24 Kudos Pharmaceuticals Limited Pharmaceutical formulation 514
WO2010056662A1 (en) 2008-11-11 2010-05-20 University Of Washington Activated wnt-beta-catenin signaling in melanoma
ES2422263T3 (es) 2008-12-19 2013-09-10 Nerviano Medical Sciences Srl Pirazoles bicíclicos como inhibidores de la proteinquinasa
AR075180A1 (es) 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
WO2010100127A1 (en) 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
TWI532484B (zh) 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
EP3045457B1 (en) 2009-06-15 2018-05-09 Nerviano Medical Sciences S.r.l. Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
KR101256018B1 (ko) 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
AU2011209234B2 (en) 2010-01-27 2015-05-07 Nerviano Medical Sciences S.R.L. Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors
SG10201502484SA (en) 2010-03-30 2015-05-28 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
JP5938038B2 (ja) 2010-08-03 2016-06-22 ネルヴィアーノ・メディカル・サイエンシズ・ソチエタ・ア・レスポンサビリタ・リミタータ ピラゾロフェニル−ベンゼンスルホンアミド化合物の誘導体及びその抗腫瘍薬としての使用
HUE032100T2 (en) 2011-03-21 2017-08-28 Valcuria Ab A pharmaceutical composition comprising an HDAC inhibitor and a steroid and its use
CN103608012A (zh) 2011-06-14 2014-02-26 诺华股份有限公司 在癌症如骨髓增殖性肿瘤治疗中的帕比司他与鲁索利替尼的组合
CA2856406C (en) 2011-11-23 2020-06-23 Novartis Ag Pharmaceutical formulations
HK1214765A1 (zh) 2012-11-08 2016-08-05 Novartis Ag 包含b-raf抑制剂和组蛋白脱乙酰基酶抑制剂的药物组合以及其在治疗增生性疾病中的用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2402602C1 (ru) * 2009-02-12 2010-10-27 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Rac, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН
WO2011025927A1 (en) * 2009-08-28 2011-03-03 Irm Llc Compounds and compositions as protein kinase inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PIZZOLATO N. et al. Stochastic dynamics of leukemic cells under an intermittent targeted therapy// Theory Biosci. 2011 Sep;130(3):203-10. TOMASETTI C. et al. An elementary approach to modeling drug resistance in cancer// Math Biosci Eng. 2010 Oct;7(4):905-18. *
ЧИССОВ В.И. и др. "Онкология. Национальное руководство"//М., ГЭОТАР-Медиа, с.848-862. *
ЧИССОВ В.И. и др. "Онкология. Национальное руководство"//М., ГЭОТАР-Медиа, с.848-862. PIZZOLATO N. et al. Stochastic dynamics of leukemic cells under an intermittent targeted therapy// Theory Biosci. 2011 Sep;130(3):203-10. TOMASETTI C. et al. An elementary approach to modeling drug resistance in cancer// Math Biosci Eng. 2010 Oct;7(4):905-18. *

Also Published As

Publication number Publication date
US11007194B2 (en) 2021-05-18
EP2776037B1 (en) 2019-01-09
RU2014117707A (ru) 2015-12-20
MX2014005726A (es) 2014-05-28
EP2776037A1 (en) 2014-09-17
US20140275136A1 (en) 2014-09-18
BR112014011223A2 (pt) 2017-05-09
WO2013070996A1 (en) 2013-05-16
CN103917236A (zh) 2014-07-09
HK1198920A1 (en) 2015-06-19
AU2012335663A1 (en) 2014-05-29
BR112014011223A8 (pt) 2023-01-31
CN108542906A (zh) 2018-09-18
MX354725B (es) 2018-03-16
CA2855243C (en) 2020-04-14
JP6150813B2 (ja) 2017-06-21
JP2014533272A (ja) 2014-12-11
AU2012335663B2 (en) 2015-12-24
CA2855243A1 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
US11007194B2 (en) Method of treating a proliferative disease
US20240299388A1 (en) Erk1/2 and shp2 inhibitors combination therapy
Furukawa Molecular targeting therapy for pancreatic cancer: current knowledge and perspectives from bench to bedside
Hofmann et al. Molecular mechanisms of resistance to kinase inhibitors and redifferentiation in thyroid cancers
JP2019532051A5 (enExample)
Spengler et al. Vemurafenib‐induced granulomatous hepatitis
Naraev et al. Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors
US20190134034A1 (en) Method of Treating Liver Cancer
MG Saez Treatment directed to signalling molecules in patients with advanced differentiated thyroid cancer
Ho et al. Cancer Management by Tyrosine Kinase Inhibitors: Efficacy
Ding et al. Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2
JP2018502089A5 (enExample)
US11406627B2 (en) Combinations of MDM2 inhibitors with inhibitors of ERK for treating cancers
US20250120978A1 (en) Jak inhibitor with erk1/2 and/or shp2 inhibitors combination therapy
Pasqualetti et al. The emerging role of sunitinib in the treatment of advanced epithelial thyroid cancer: our experience and review of literature
HK1198920B (en) Method of treating a proliferative disease
Palmieri et al. Resistance to targeted therapies in melanoma: new insights
Khan et al. An update on BRAF inhibitors and other new molecular targets for the treatment of malignant melanoma of the skin
WO2026107237A1 (en) Ras and egfr inhibitors combination therapy
CN117897158A (zh) Erk1/2和shp2抑制剂组合疗法
CA3222730A1 (en) Erk1/2 and egfr inhibitors combination therapy
WO2022271935A1 (en) Erk1/2 inhibitor combination therapy
Simoneaux Combination Therapy for Metastatic Melanoma
RU2019111662A (ru) Терапевтические комбинации, содержащие ингибитор raf и ингибитор erk
CN117940132A (zh) Erk1/2和kras g12c抑制剂组合疗法

Legal Events

Date Code Title Description
PC41 Official registration of the transfer of exclusive right

Effective date: 20211005